As of 2026-11-13, the Fair Value of Nektar Therapeutics (NKTR) is -50.79 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 37.25 USD, the upside of Nektar Therapeutics is -236.35%.
With the market price of 37.25 USD and our fair value calculation, Nektar Therapeutics (NKTR) is not a good investment. Investing in NKTR stocks now will result in a potential loss of 236.35%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | 5Y Avg | |
| Net income | -523.80 | -368.20 | -276.06 | -118.96 | -164.08 | -290.22 |
| YoY growth | -17.87% | 29.71% | 25.03% | 56.91% | -37.92% | 11.17% |
| Market Cap (mil) | 1,271.72 |
| P/E | |
| Forward P/E |
| EPS | -4.55 |
| Avg earnings growth rate | 11.17% |
| TTM earnings | -155.25 |